Top

Published in:

01-05-2013 | Editorial

Celiac Disease: Clinch the Diagnosis When It Is Just Around the Corner

Authors: Pekka Collin, Katri Kaukinen

Published in: Digestive Diseases and Sciences | Issue 5/2013

Excerpt

Although a considerable number of publications have reported that the prevalence of celiac disease is 1–2 %, fewer have reported the diagnostic accuracy of the screening tests used [1, 2]. Since the classic symptoms of steatorrhea and malabsorption constitute only a minor subgroup of the subjects with celiac disease, active case finding with suitable tests is needed to identify the disease widely. …

Katz KD, Rashtak S, Lahr BD, et al. Screening for celiac disease in a North American population: sequential serology and gastrointestinal symptoms. Am J Gastroenterol. 2011;106:1333–1339.PubMedCrossRef

Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of celiac disease among children in Finland. N Engl J Med. 2003;348:2517–2524.PubMedCrossRef

Collin P. Should adults be screened for celiac disease? What are the benefits and harms of screening? Gastroenterology. 2005;128:S104–S108.PubMedCrossRef

Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd. Trends in the identification and clinical features of celiac disease in a North American community, 1950–2001. Clin Gastroenterol Hepatol. 2003;1:19–27.PubMedCrossRef

Lebwohl B, Bhagat G, Markoff1 S, et al. Prior endoscopy in patients with newly diagnosed celiac disease; a missed opportunity? Dig Dis Sci. (Epub ahead of print). doi: 10.1007/s10620-012-2551-3.

Virta L, Kaukinen K, Collin P. Incidence and prevalence of diagnosed coeliac disease in Finland: results of effective case finding in adults. Scand J Gastroenterol. 2009;44:933–938.PubMedCrossRef

Collin P, Rasmussen M, Kyrönpalo S, Kaukinen K. The hunt for coeliac disease in primary care. Q J Med. 2002;95:75–77.CrossRef

Lebwohl B, Tennyson CA, Holub JL, Lieberman DA, Neugut AI, Green PH. Sex and racial disparities in duodenal biopsy to evaluate for celiac disease. Gastrointest Endosc. 2012;76:779–785.PubMedCrossRef

Collin P, Kaukinen K, Vogelsang H, et al. Anti-endomysial and anti-human recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study. Eur J Gastoenterol Hepatol. 2005;17:85–91.CrossRef

10.

Salmi TT, Collin P, Korponay-Szabo IR, et al. Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits. Gut. 2006;55:1746–1753.PubMedCrossRef

11.

Dickey W, Hughes DF, McMillan SA. Patients with serum IgA endomysial antibodies and intact duodenal villi: clinical characteristics and management options. Scand J Gastroenterol. 2005;40:1240–1243.PubMedCrossRef

12.

Järvinen TT, Collin P, Rasmussen M, et al. Villous tip intraepithelial lymphocytes as markers of early stage coeliac disease. Scand J Gastroenterol. 2004;39:428–433.PubMedCrossRef

13.

Biagi F, Luinetti O, Campanella J, et al. Intraepithelial lymphocytes in the villous tip: do they indicate potential coeliac disease? J Clin Pathol. 2004;57:835–839.PubMedCrossRef

Title: Celiac Disease: Clinch the Diagnosis When It Is Just Around the Corner
Authors: Pekka Collin
Katri Kaukinen
Publication date: 01-05-2013
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 5/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-013-2651-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2013

Prior Endoscopy in Patients with Newly Diagnosed Celiac Disease: A Missed Opportunity?

Dietary Patterns and Self-Reported Associations of Diet with Symptoms of Inflammatory Bowel Disease

Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy

Double Tract Reconstruction After Gastrectomy Facilitates Endoscopic Access to the Biliary Tree

Glycyrrhizin Enhances Therapeutic Activity of a Colon-Specific Methylprednisolone Prodrug Against Experimental Colitis

Acid Suppression Therapy as a Risk Factor for Candida Esophagitis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials